All In Biotech

Drug Trial Radar · NCT06908577

An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I Pharmacokinetic Comparability Study of Tozorakimab Administered Using an Accessorised Prefilled Syringe (APFS) or an Autoinjector (AI) in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Apr 7, 2025

Primary completion

Nov 25, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • TozorakimabDrug

    Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.

  • Autoinjector (AI) DeviceDevice

    AI device will be used to administer single SC dose of tozorakimab on Day 1.

  • Accessorised Prefilled Syringe (APFS) DeviceDevice

    APFS device will be used to administer single SC dose of tozorakimab on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) of tozorakimabTime frame: From Day 1 to Day 113
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of tozorakimabTime frame: From Day 1 to Day 113
  3. Maximum observed drug concentration (Cmax) of tozorakimabTime frame: From Day 1 to Day 113

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Baltimore, Maryland

  • Research Site

    Berlin, Germany

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.